Key result
Low-dose (25 IU/kg) 4PCC demonstrated similar hemostatic efficacy compared to standard-dose (50 IU/kg) 4PCC for factor Xa inhibitor reversal in intracranial hemorrhage (82.3% vs 83.9%; P=0.846).
Why the study?
Guidelines recommend 50 IU/kg 4PCC for factor Xa inhibitor reversal in ICH based on non-ICH studies, but low-dose 25 IU/kg is also used, and no studies had directly compared these two doses for this indication.
Does low-dose (25 IU/kg) 4PCC provide similar hemostatic efficacy compared to standard-dose (50 IU/kg) 4PCC for factor Xa inhibitor reversal in patients with intracranial hemorrhage?
Cohort (n=93)
Yes
Does low-dose (25 IU/kg) 4PCC provide similar hemostatic efficacy compared to standard-dose (50 IU/kg) 4PCC for factor Xa inhibitor reversal in patients with intracranial hemorrhage?
A 25 IU/kg dose of 4PCC demonstrates similar hemostatic efficacy to the guideline-recommended 50 IU/kg dose for factor Xa inhibitor reversal in intracranial hemorrhage.
Low-dose 4PCC may suffice for FXaI reversal in ICH; leaves open optimal dosing pending prospective trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Cascone et al. (2021) conducted a cohort in Intracranial hemorrhage requiring factor Xa inhibitor reversal (n=93). Low-dose four-factor prothrombin complex concentrate (4PCC) vs. Standard-dose (50 IU/kg) 4PCC was evaluated on Hemostatic efficacy (p=0.846). Low-dose (25 IU/kg) 4PCC demonstrated similar hemostatic efficacy compared to standard-dose (50 IU/kg) 4PCC for factor Xa inhibitor reversal in intracranial hemorrhage (82.3% vs 83.9%; P=0.846).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: